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Abstract
Occasionally, multiple names are given to the same gene/protein. When this happens, different
names can be used in subsequent publications, for example in different research areas, sometimes
with little or no awareness that the same entity known under a different name may have a major
role in another field of science. Recent reports about the protein p11 presented findings that this
protein, commonly known as S100A10, may play a crucial role in depression and antidepressant
treatment mechanisms. One set of data showed an increased expression of this protein in the brain
of mice treated with antidepressants. P11/S100A10 is only one of several S100 proteins expressed
in the brain. Interestingly, it has been previously noted that antidepressant treatment increases the
brain content of another S100 protein, S100B. It appears that up-regulating the brain content of
various S100 proteins might be a common feature of antidepressants. In cells coexpressing
S100A10 and S100B, these proteins may interact and exert opposite regulatory roles.
Nevertheless, S100A10 is predominantly expressed in certain types of neurons whereas S100B is
more abundant in glia. Thus, an interplay among multiple members of the S100 proteins might be
important in determining the region and cell specificity of antidepressant mechanisms. Calling the
p11 protein by its other name, S100A10, may prompt more investigators from different fields to
participate in this new direction of neurobiological research.
Introduction
What's in a name? ["What's in a name? That which we call a
rose by any other word would smell as sweet." Act II, scene 2
from Romeo and Juliet; W. Shakespeare]. Sometimes more
than it appears on the first glance. A choice of names, jar-
gon, or terminology shapes the way we view the world [1].
Naming things is an integral part of scientific discovery.
Newly discovered entities need names. The discoverers
sometimes are indulgent in choosing names for their find-
ings. Particularly playful is the Drosophila  (fruit fly)
research community when it comes to naming new genes.
For example, Cheapdate is a gene that influences whether
flies offered alcohol become quickly drunk, thus a "cheap
date" [2]. Indy is an acronym for "I am not dead yet,"
based on a comical line in the movie Monty Python and the
Holy Grail, and describes a gene that extends the life of
flies [3].
These are examples of intentionally humorous and pro-
vocative names given to serious discoveries. More often,
serious discoveries bear boring and technical names.
Occasionally, multiple names are given to a same entity,
exemplifying how sometimes the same discoveries can be
made multiple times by groups unaware of each other's
findings. When this happens, multiple names can be used
in subsequent publications, for example in different
research areas, sometimes with little or no awareness that
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the same entity known under a different name may have
a major role in another field of science.
"A new molecule to brighten the mood"
This title was used in a recent issue of Science [4] to popu-
larly describe the scientific findings reported in the peer-
reviewed portion of the same issue of this journal [5]. The
published findings point to a novel interaction between a
protein called p11 and serotonin (5-hydroxytryptamine;
5-HT) receptors called 5-HT1B. It was proposed that the
reported protein-protein interactions might be involved
in the pathobiology of depression (a psychiatric illness
attributed in part to 5-HT disturbances) and in the mech-
anism of action of antidepressant drugs (many of which
are selective 5-HT reuptake inhibitors). Various forms of
the Science-generated catchy title about the "new molecule
p11" have been adopted by other media outlets around
the world and established their roots in the everlasting
www, for example [6]. Is p11 indeed a completely new
molecule when it comes to antidepressant effects?
S100 proteins and antidepressants
The discovery by Svenningsson et al. [5] is important, and
the route that led to the finding that 5-HT1B receptors
directly interact with p11 and that p11 increases localiza-
tion of 5-HT1B receptors at the cell surface has not been
predicted based on previously published association
between these proteins. Furthermore, the authors found
that in the postmortem brain of depressed subjects p11
protein levels are lower compared to the samples from
non-depressed subjects. Moreover, experimental animals
treated with antidepressants had elevated brain levels of
p11, suggesting that antidepressants could be helpful
because they increase p11, which brings more 5-HT1B
receptors to neuronal membranes to be available for acti-
vation by their neurotransmitter 5-HT. Is there any previ-
ous work that could link p11 to antidepressants? A
PubMed search (January 20, 2006) on "p11" & "antidepres-
sant" generated only 1 hit, the paper by Svenningsson et
al. [5].
However, in their paper, Svenningsson et al. mentioned
that p11 is also known by different names: "S100A10, cal-
pactin I light chain, and annexin II light chain". It was pro-
posed [4] that since p11 belongs to the family of S100
proteins and because these proteins can be regulated by
glucocorticoids (stress hormones), the stress effects on
p11 could explain the link between stress and the patho-
biology of depression.
Whereas the PubMed searches on "calpactin I" & "antide-
pressant" and "annexin II" & "antidepressant" did not pro-
duce results, a search on "S100" & "antidepressant" resulted
in 19 citations. The first (i.e., the oldest) report was from
1993 [7], pointing to a link between antidepressants, 5-
HT1A receptors, and the glia release of S100B protein. Nev-
ertheless, the concept of glia-secreted S100B as a mediator
of antidepressant activity proposed in that paper was
unrelated to the currently proposed association of antide-
pressants, 5-HT1B receptors, and the S100A10 protein.
The S100 protein family comprises 19 members [8], most
of which are expressed in the brain [9]. The issue of sys-
tematically naming various S100 proteins has been recog-
nized in the past and Schafer et al. [10] proposed specific
and logical nomenclature of these proteins that has been
widely accepted. According to this nomenclature, p11 is
named S100A10. Interestingly, it was previously found
that, similar to their stimulatory effect on the brain con-
tent of S100A10 [5], antidepressants also increase the
brain, i.e., hippocampal content of S100B [11-13], and it
has been proposed that S100B-related mechanisms could
become targets for a novel antidepressant therapy [14,15].
In cells coexpressing S100A10 and S100B, these proteins
may interact and exert opposite regulatory roles; e.g., on
the assembly of the glial fibrillary acidic protein (GFAP)
[8]. Since it appears that S100A10 is predominantly
expressed in certain types of neurons, whereas S100B is
more abundant in glia, S100 proteins might be important
in determining the region and cell specificity of antide-
pressant mechanisms. Experiments designed to consider a
more general role of S100 proteins in depression and anti-
depressant mechanisms as opposed to focusing solely on
S100A10 might generate important new findings.
Conclusion
It appears that up-regulating the brain content of various
S100 proteins might be a common feature of antidepres-
sants. The sophisticated set of experiments published by
Svenningsson et al. suggests that p11/S100A10 may con-
tribute to antidepressant activity by interacting with sero-
tonin 5-HT1B receptors and by increasing their membrane
presence and availability. In light of previously published
studies it would be worth exploring whether S100B and
other S100 proteins also affect a cell membrane insertion
of some receptor proteins. The work by Svenningsson et
al. [5] provides an important impetus for further clarifying
the role of S100 proteins in depression, and calling their
p11 protein by its more appropriate S100A10 name may
prompt more investigators from different fields to partici-
pate in this exciting new research direction.
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